Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.

[1]  Q. Wei,et al.  Effect of Polymorphisms in XPD on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients , 2012, PloS one.

[2]  Wei Wu,et al.  Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis , 2012, BMC Cancer.

[3]  J. Yokota,et al.  Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Hongbing Shen,et al.  Prognostic Significance of Survivin Polymorphisms on Non-small Cell Lung Cancer Survival , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  J. Park,et al.  Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non‐small‐cell lung cancer , 2010, Cancer science.

[6]  D. Christiani,et al.  Germline genetic variation, cancer outcome, and pharmacogenetics. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Jeon,et al.  Polymorphisms in Apoptosis-Related Genes and Survival of Patients with Early-Stage Non-Small-Cell Lung Cancer , 2010, Annals of Surgical Oncology.

[8]  Lin-Yu Lu,et al.  The role of BRCA1 in DNA damage response , 2010, Protein & Cell.

[9]  Peter M. Ellis,et al.  First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Dong Sun Kim,et al.  Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Yuxin Zheng,et al.  Association between X-ray repair cross complementing group 1 codon 399 and 194 polymorphisms and lung cancer risk: a meta-analysis. , 2009, Cancer letters.

[12]  R. Dahiya,et al.  The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer. , 2009, The Journal of urology.

[13]  A. Bankfalvi,et al.  The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  S. Novello,et al.  Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Shin,et al.  Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[17]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[19]  C. H. Kim,et al.  Polymorphisms in the survivin gene and the risk of lung cancer. , 2008, Lung cancer.

[20]  M. Spitz,et al.  Genetic Variants in Cell Cycle Control Pathway Confer Susceptibility to Lung Cancer , 2007, Clinical Cancer Research.

[21]  P. Mullan,et al.  BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment? , 2006, Biochimica et biophysica acta.

[22]  R. Millikan,et al.  Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. , 2006, American journal of human genetics.

[23]  N. Crawford,et al.  Germ line polymorphism in metastatic progression. , 2006, Cancer research.

[24]  H. Dienemann,et al.  Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. , 2004, Carcinogenesis.

[25]  E. Felip,et al.  BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. , 2004, Human molecular genetics.

[26]  Yong Xu,et al.  A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. , 2004, DNA and cell biology.

[27]  A. Loktionov.  Common gene polymorphisms, cancer progression and prognosis. , 2004, Cancer letters.

[28]  J. Minna,et al.  Molecular genetics of lung cancer. , 2003, Seminars in oncology.

[29]  M. Spitz,et al.  Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. , 2003, Lung cancer.

[30]  P. Johnston,et al.  BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.

[31]  R. Ramlau,et al.  Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Christopher I Amos,et al.  Genetic susceptibility to lung cancer: the role of DNA damage and repair. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  K. Hemminki,et al.  The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. , 2002, Carcinogenesis.

[34]  J. Park,et al.  Lys751Gln polymorphism in the DNA repair gene XPD and risk of primary lung cancer. , 2002, Lung cancer.

[35]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[36]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[37]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[38]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[39]  K. Jöckel,et al.  Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. , 2007, Blood.

[40]  C. H. Kim,et al.  Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.